<DOC>
	<DOC>NCT00191620</DOC>
	<brief_summary>The purposes of this study are to determine: How standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer. The safety of standard gemcitabine plus cisplatin and any side effects that might be associated with it as compared to a fixed dose rate of gemcitabine plus cisplatin.</brief_summary>
	<brief_title>Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>At least 18 years of age Histologically or cytologically confirmed diagnosis of NSCLC Have provided written informed consent Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Adequate organ function Prior chemotherapy or biologic therapy (approved or experimental) for NSCLC Presence of uncontrolled central nervous system (CNS) metastases Inability to comply with protocol or study procedures Pregnancy Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>